コンテンツにジャンプ

トップページ > 研究組織一覧 > 基盤的臨床開発研究コアセンター > 創薬標的・シーズ探索部門 > 論文業績

論文業績

2023年

  1. Matsuzaki M, Kato K, Oono K, Tsuchiya N, Sudo K, Shimomura A, Tamura K, Shiino S, Kinoshita T, Daiko H, Wada T, Katai H, Ochiai H, Kanemitsu Y, Takamaru H, Abe S, Saito Y, Boku N, Kondo S, Ueno H, Okusaka T, Shimada K, Ohe Y, Asakura K, Yoshida Y, Watanabe SI, Asano N, Kawai A, Ohno M, Narita Y, Ishikawa M, Kato T, Fujimoto H, Niida S, Sakamoto H, Takizawa S, Akiba T, Okanohara D, Shiraishi K, Kohno T, Takeshita F, Nakagama H, Ota N, Ochiya T; Project Team for Development and Diagnostic Technology for Detection of miRNA in Body Fluids. Prediction of tissue-of-origin of early stage cancers using serum miRNomes. JNCI Cancer Spectr. 7 (1): pkac080, 2023.
  2. Kanda M, Serada S, Hiramatsu K, Funauchi M, Obata K, Nakagawa S, Ohkawara T, Murata O, Fujimoto M, Chiwaki F, Sasaki H, Ueda Y, Kimura T, Naka T. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer. Neoplasia. 35: 100853, 2023

2022年

  1. Komatsu M, Ichikawa H, Chiwaki F, Sakamoto H, Komatsuzaki R, Asaumi M, Tsunoyama K, Fukagawa T, Matsushita H, Boku N, Matsusaki K, Takeshita F, Yoshida T, Sasaki H. ARHGAP-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer. Oncogene, 41 (43): 4779-4794, 2022.
  2. Urabe F, Matsuzaki J, Takeshita F, Kishida T, Ochiya T, Hirai K. Independent verification of circulating miRNA as diagnostic biomarkers for urothelial carcinoma. Cancer Sci. Oct;113(10):3510-3517, 2022.
  3. Prieto-Vila M, Usuba W, Yoshioka Y, Takeshita F, Yoshiike M, Sasaki H, Yamamoto Y, Kikuchi E, Ochiya T. High-grade bladder cancer cells secrete extracellular vesicles containing miRNA-146a-5p and promotes angiogenesis. J of Extracellular Bio. 1 (8): e47, 2022.
  4. Komatsu M, Nakamura K, Takeda T, Chiwaki F, Banno K, Aoki D, Takeshita F, Sasaki H. Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signaling. Oncogene. 41 (16): 2326-2339, 2022.
  5. Kobayashi Y, Takeda T, Kunitomi H, Chiwaki F, Komatsu M, Nagai S, Nogami Y, Tsuji K, Masuda K, Ogiwara H, Sasaki H, Banno K, Aoki D. Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer. Pharmaceuticals (Basel). 15(2): 124, 2022

2021年

  1. Abe S, Matsuzaki J, Sudo K, Oda I, Katai H, Kato K, Takizawa S, Sakamoto H, Takeshita F, Niida S, Saito Y, Ochiya T. A novel combination of serum microRNAs for the detection of early gastric cancer. Gastric Cancer. 24 (4): 835-843. 2021.
  2. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sei A, Takeshita F, Sugaya J, Fukushima S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Hum Cell. 34 (1): 260-270, 2021.
  3. Zhou Y, Yamamoto Y, Takeshita F, Yamamoto T, Xiao Z, Ochiya T. Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment. Int J Mol Sci. 22 (2) : 844, 2021.
  4. Sugano T, Masuda M, Takeshita F, Motoi N, Hirozane T, Goto N, Kashimoto S, Uno Y, Moriyama H, Sawa M, Nagakawa Y, Tsuchida A, Seike M, Gemma A, Yamada T. Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. Br J Cancer. 124: 228-236, 2021.
  5. Tanaka Y, Chiwaki F, Kojima S, Kawazu M, Komatsu M, Ueno T, Inoue S, Sekine S, Matsusaki K, Matsushita H, Boku N, Kanai Y, Yataba Y, Sasaki H, and Mano H. Molti-omic profiling of peritoneal metastasis in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat. Cancer. 2021 Aug. doi.org/10.1038/s43018-021-00240-6.

2020年

  1. Sanchez Calle A, Yamamoto T, Kawamura Y, Hironaka-Mitsuhashi A, Ono M, Tsuda H, Shimomura A, Tamura K, Takeshita F, Ochiya T, Yamamoto Y. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers. Mol Oncol. 14: 2271-2287, 2020.
  2. Kurashima K, Kashiwagi H, Shimomura I, Suzuki A, Takeshita F, Mazevet M, Harata M, Yamashita T, Yamamoto Y, Kohno T, Shiotani B. SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma. NAR Cancer 2: zcaa005, 2020.
  3. Liew LC, Gailhouste L, Tan GC, Yamamoto Y, Takeshita F, Nakagama H, Ochiya T. MicroRNA-124a inhibits endoderm lineage commitment by targeting Sox17 and Gata6 in mouse embryonic stem cells. Stem Cells. 38: 504-515, 2020.
  4. Sasaki M, Chiwaki F, Kuroda T, Komatsu M, Matsusaki K, Kohno T, Sasaki H, and Ogiwara H. Efficacy of Glutathione Inhibitors for the Treatment of ARID1A-Deficient Diffuse-Type Gastric Cancers. Biochem Biophys Res Commun. 2020 Feb 5;522(2):342-347. doi: 10.1016/j.bbrc.2019.11.078. Epub 2019 Nov 22. PMID:31761322

2019年

  1. Yamamoto Y, Kondo S, Matsuzaki J, Esaki M, Okusaka T, Shimada K, Murakami Y, Enomoto M, Tamori A, Kato K, Aoki Y, Takizawa S, Sakamoto H, Niida S, Takeshita F, Ochiya T. Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease. Hepatol Commun. 4: 284-297, 2019.
  2. Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, Daiko H, Takizawa S, Aoki Y, Sakamoto H, Niida S, Takeshita F, Fukuda T, Ochiya T. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling. JAMA Netw Open. 2: e194573, 2019.
  3. Ogiwara H, Takahashi K, Sasaki M, Kuroda T, Watanabe R, Yoshida H, Maruyama A, Makinoshima H, Chiwaki F, Sasaki H, Kato T, Okamoto A, and Kohno T. Targeting Vulnerability of Glutathione Metabolic Pathway in ARID1A-Deficient Cancers. Cancer Cell, 2019 Feb 11;35(2):177-190.e8. doi: 10.1016/j.ccell.2018.12.009. PMID: 30686770
  4. Takeda T, Komatsu M, Chiwaki F, Komatsuzaki R, Nakamura K, Tsuji K, Kobayashi Y, Tominaga E, Ono M, Banno K, Aoki D, Sasaki H. Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsin. Cell Death Dis. 10(102): 876, 2019

2018年

  1. Fujiwara Y, Saito M, Robles AI, Nishida M, Takeshita F, Watanabe M, Ochiya T, Yokota J, Kohno T, Harris CC, Tsuchiya N. A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network. 33, 33-48, 2018.
  2. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. The Emerging Roles of Long Non-coding RNA in Cancer. Cancer Sci., 109, 2098-2100, 2018.

2017年

  1. Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T, Kiyono T, Takeshita F, Kajiyama H, Kikkawa F, Ochiya T. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Commun., 8: 14470, 2017.
  2. Nishida-Aoki N, Tominaga N, Takeshita F, Sonoda H, Yoshioka Y, Ochiya T. Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis. Mol Ther., 25, 181-191, 2017.
  3. Nagasato M, Rin Y, Yamamoto Y, Henmi M, Hiraoka N, Chiwaki F, Matsusaki K, Tagawa M, Sasaki H, Aoki K. A tumor-targeting adenovirus with high gene-transduction efficiency for primary pancreatic cancer and ascites cells.Anticancer Res, 37: 3599-3605, 2017.

2016年

  1. Kubota D, Kosaka N, Fujiwara T, Yoshida A, Arai Y, Qiao Z, Takeshita F, Ochiya T, Kawai A, Kondo T. miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. Sarcoma. 2016時13分90571, 2016.
  2. Miura N, Kamita M, Kakuya T, Fujiwara Y, Tsuta K, Shiraishi H, Takeshita F, Ochiya T, Shoji H, Huang W, Ohe Y, Yamada T, Honda K. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget , 7, 33165-33178, 2016.
  3. Hirahata M, Osaki M, Kanda Y, Sugimoto Y, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Kawai A, Ito H, Ochiya T, Okada F. PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma. Cancer Med., 5, 892-902, 2016.
  4. Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, Fujiwara Y, Kinoshita T, Kenji Tand Ochiya T. A novel combination of serum microRNAs for detecting breast cancer in the early stage. Cancer Sci., 107, 326-334, 2016.

2015年

  1. Kosaka T, Davydova J, Ono HA, Akiyama H, Hirai S, Ohno S, Takeshita F, Aoki K, Ochiya T, Yamamoto M, Kunisaki C, Endo I. Imaging and Antitumoral Effect of a Cyclo-oxygenase 2-specific Replicative Adenovirus for Small Metastatic Gastric Cancer Lesions. Anticancer Res. 35:5201-5210, 2015.
  2. Urata UN*, Takeshita F*, Tanaka H, Ochiya T and Takimoto M.: Targeted Knockdown of the Kinetochore Protein D40/Knl-1 Inhibits Human Cancer in a p53 Status-Independent Manner. Rep., 5, 13676, 2015. (*, Contributed equally)
  3. Takahashi RU, Miyazaki H, Takeshita F, Yamamoto Y, Minoura K, Ono M, Kodaira M, Tamura K, Mori M, and Ochiya T.: Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ectonucleotide pyrophosphatase 1. Commun., 6: 7318, 2015.
  4. Ono M, Tsuda H, Kobayashi T, Takeshita F, Takahashi RU, Tamura K, Akashi-Tanaka S, Moriya T, Yamasaki T, Kinoshita T, Yamamoto J, Fujiwara Y, Ochiya T.: The expression and clinical significance of ribophorin II (RPN2) in human breast cancer. Pathol Int., 65, 301-108, 2015.
  5. Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T, Asamura H, Kawaishi M, Kuwano K, Ochiya T.: The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther., 23, 717-727, 2015.
  6. Fujita Y, Yagishita S, Takeshita F, Yamamoto Y, Kuwano K, Ochiya T.: Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer. Oncotarget 6, 3335-3345, 2015.
  7. Yamanoi K, Arai E, Tian Y, Takahashi Y, Miyata S, Sasaki H, Chiwaki F, Ichikawa H, Sakamoto H, Kushima R, Katai H, Yoshida T, Sakamoto M, and Kanai Y. Epigenetic clustering of gastric carcinomas based on DNA methylation profiles at the precancerous stage: its correlation with tumor aggressiveness and patient outcome. Carcinogenesis, 36: 509-520, 2015.
  8. Suzuki M, Chiwaki F, Sawada Y, Ashikawa M, Aoyagi K, Fujita T, Yanagihara K, Komatsu M, Narita M, Suzuki T, Nagase H, Kushima R, Sakamoto H, Fukagawa T, Katai H, Nakagama H, Yoshida T, Uezono Y, and Sasaki H. Peripheral opioid antagonist enhances the effect of anti-tumor drug by blocking a cell growth-suppressive pathway in vivo. PLoS One, 10(4): e0123407, 2015.
  9.  Fujita T, Chiwaki F, Takahashi R, Aoyagi K, Yanagihara K, Nishimura T, Tamaoki M, Komatsu M, Komatsuzaki R, Matsusaki K, Ichikawa H, Sakamoto H, Yamada Y, Fukagawa T, Katai H, Konno H, Ochiya T, Yoshida T, and Sasaki H. Identification and characterization of CXCR4-positive gastric cancer stem cells. PLoS One, 10(6): e0130808, 2015.

2014年

  1. Fujita Y, Kuwano K, Ochiya T, Takeshita F.: The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research. Res. Int., 2014: 486413, 2014.
  2. Kurioka D, Takeshita F, Tsuta K, Sakamoto H, Watanabe S, Matsumoto K, Watanabe M, Nakagama H, Ochiya T, Yokota J, Kohno T, Tsuchiya N.: NEK9-dependent proliferation of cancer cells lacking functional p53. Rep., 4:6111, 2014.
  3. Seino S, Takeshita F, Asari A, Masuda Y, Kunou M, Ochiya T.: No Influence of Exogenous Hyaluronan on the Behavior of Human Cancer Cells or Endothelial Cell Capillary Formation. Food Sci., 79: T1469-1475, 2014.
  4. Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, Yoshida M, Tsuda H, Tamura K, Ochiya T.: Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal. 7: 332, 2014.
  5. Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, Furuta K, Nakajima T, Hayashi H, Sugisaki H, Higashimoto H, Kato T, Takeshita F, Ochiya T.: Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Commun., 5: 3591, 2014.
  6. Otsubo C, Otomo R, Miyazaki M, Matsushima-Hibiya Y, Kohno, T, Iwakawa R, Takeshita F, Okayama H, Ichikawa H, Saya H, Kiyono T, Ochiya T, Tashiro F, Nakagama H, Yokota J, Enari M.: TSPAN2 Is Involved in Cell Invasion and Motility during Lung Cancer Progression. Cell Reports, 7時52分7-538, 2014.
  7. Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota K, Kondo T, Ichikawa H, Yoshida A, Kobayashi E, Kawai A, Ozaki T, Ochiya T: Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells, 32: 959-973, 2014.

2013年

  1. Fujita Y, Takeshita F, Mizutani T, Ohgi T, Kuwano K, Ochiya T: A novel platform to enable inhaled naked RNAi medicine for lung cancer. Rep., 3: 3325, 2013.
  2. Takahashi RU, Takeshita F, Honma K, Ono M, Kato K, Ochiya T: Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β. Rep., 3: 2474, 2013. 
  3. Uchino K, Ochiya T, Takeshita F*: RNAi therapeutics and applications of microRNAs in cancer treatment. J. Clin. Oncol., 43: 596-607, 2013. (*, Corresponding author)
  4. Katsuda T, Kosaka N, Takeshita F, Ochiya T: The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics, 13: 1637-1653, 2013.
  5. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T.: Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem., 288:10849-10859, 2013.
  6. Kosaka N, Takeshita F, Yoshioka Y, Hagiwara K, Katsuda T, Ono M, Ochiya T: Exosomal tumor-suppressive microRNAs as novel cancer therapy: "Exocure" is another choice for cancer treatment. Adv Drug Deliv Rev., 65, 376-382, 2013.
  7. Uchino K, Takeshita F, Takahashi RU, Kosaka N, Fujiwara K, Naruoka H, Sonoke S, Yano J, Sasaki H, Nozawa S, Yoshiike M, Kitajima K, Chikaraishi T, Ochiya T: Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther., 21, 610-619, 2013.
  8. Fujita T, Yanagihara K, Takeshita F, Aoyagi K, Nishimura T, Takigahira M, Chiwaki F, Fukagawa T, Katai H, Ochiya T, Sakamoto H, Konno H, Yoshida T, Sasaki H: Intraperitoneal delivery of a small interfering RNA targeting NEDD1 prolongs the survival of scirrhous gastric cancer model mice. Cancer Sci., 104, 214-222, 2013.
  9. Fujita Y, Takeshita F, Kuwano K, Ochiya T: RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals, 6, 223-225, 2013.
  10. Katsuda T, Tsuchiya R, Kosaka N, Yoshioka Y, Takagaki K, Oki K, Takeshita F, Sakai Y, Kuroda M, Ochiya T: Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Rep., 3: 1197, 2013.

2012年

  1. Takeshita F, Takahashi RU, Onodera J, Ochiya T: In vivo imaging of oligonucleotide delivery. Methods Mol. Biol., 872, 243-253, 2012.
  2. Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Ochiya T: Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Rep., 2, 314, 2012.
  3. Hirose Y, Saijou E, Sugano Y, Takeshita F, Nishimura S, Nonaka H, Chen YR, Sekine K, Kido T, Nakamura T, Kato S, Kanke T, Nakamura K, Nagai R, Ochiya T, Miyajima A: Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Natl. Acad. Sci. USA, 109, 4263-4268, 2012.
  4. Narumi K, Udagawa T, Kondoh A, Kobayashi A, Hara H, Ikarashi Y, Ohnami S, Takeshita F, Ochiya T, Okada T, Yamagishi M, Yoshida T, Aoki K: In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. Gene Ther., 19, 34-48, 2012.

2011年

  1. Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, Ochiya T: Competitive interactions of cancer cells and normal cells via secretory microRNAs. Biol. Chem., 287: 1397-1405, 2011.
  2. Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, Horii R, Fukuoka Y, Kato T, Kosaka N, Ochiya T: An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Cancer, 10: 135, 2011.
  3. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, Ito H, Oshimura M, Ochiya T: MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression. Mol Ther., 19: 1123-1130, 2011.
  4. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H: miR-22 represses cancer progression by inducing cellular senescence. Cell Biol., 193: 409-424, 2011.

2010年

  1. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. Biol. Chem., 285: 17442-17452, 2010.
  2. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T: Combined Functional Genome Survey of Therapeutic Targets for Hepatocellular Carcinoma. Cancer Res., 16: 2518-2528, 2010.
  3. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D and Ochiya T: Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell cycle genes. Ther., 18: 181-187, 2010.
  4. Tanooka H, Tatsumi K, Tsuji H, Noda Y, Katsube T, Ishii H, Ootsuyama A, Takeshita F and Ochiya T: Mutant mouse p53 transgene elevates the chemical induction of tumors that respond to gene silencing with siRNA. Cancer Gene Ther., 17: 1-10, 2010.

2009年

  1. Takeshita F, Hokaiwado N, Honma K, Banas A and Ochiya T: Local and systemic delivery of siRNAs for oligonucleotides therapy. Methods in Mol. Biol., 487: 83-92, 2009.
  2. Honma K, Takemasa I, Matoba R, Yamamoto Y, Takeshita F, Mori M, Monden M, Matsubara K and Ochiya T: Screening of potential molecular targets for colorectal cancer therapy. J. General Med., 2: 243-257, 2009.
  3. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, Kato T, Okochi H and Ochiya T: Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure., Gastroenterol. Hepatol., 24: 70-77, 2009.

2008年

  1. Osaki M, Takeshita F and Ochiya T: MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers, 13: 658-670, 2008.
  2. Ajima R, Akazawa H, Kodama M, Takeshita F, Otsuka A, Kohno T, Komuro I, Ochiya T and Yokota J: Deficiency of Myo18B in mice results in embryonic lethality with cardiac myofibrillar aberrations. Genes Cells, 13: 987-999, 2008.
  3. Honma K, Iwao KK, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T: RPN2 gene confers docetaxel resistance in breast cancer. Med., 14: 939-948, 2008.
  4. Takahashi RU, Kanesashi SN, Inoue T, Enomoto T, Kawano MA, Tsukamoto H, Takeshita F, Imai T, Ochiya T, Kataoka K, Yamaguchi Y and Handa H: Presentation of functional foreign peptides on the surface of SV40 virus-like particles., Biotechnol., 135:385-392, 2008.
  5. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, Kawamata M, Kato T, Okochi H and Ochiya T: IFATS Collection: In vivo therapeutic potential of human Adipose Tissue Mesenchymal Stem Cells after transplantation into mice with liver injury., Stem Cells, 26: 2705-2712, 2008.
  6. Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T and Shirai T: Glutathione S-transferase pi mediates proliferation of androgen independent prostate cancer cells., Carcinogenesis,29: 1134-1138, 2008.
  7. Hokaiwado N, Takeshita F, Banas A and Ochiya T: RNAi-based drug discovery and its application to therapeutics., IDrugs, 11: 274-278, 2008.
  8. Hikosaka A, Ogawa K, Sugiura S, Asamoto M, Takeshita F, Sato SY, Nakanishi M, Kohri K and Shirai T: Susceptibility of p27 kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation., J. Cancer, 122: 1222-12228, 2008.
  9. Kodama M, Takeshita F, Kanegasaki S, Ochiya T and Quinn G: Pancreatic Endocrine and Exocrine Cell Ontogeny from Renal Capsule-Transplanted Embryonic Stem cells in Streptozocin-Injured Mice., Histochem. Cytochem., 56: 33-44, 2008.

2007年

  1. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Quinn G, Okochi H and Ochiya T: Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes., Hepatology, 46: 219-228, 2007.
  2. Honma K, Takeshita F, Ochiya T: Application of atelocollagen-mediated siRNA delivery for RNAi therapies., Yakugaku Zasshi, 127: 807-812, 2007.
  3. Ochiya T, Honma K, Takeshita F and Nagahara S: Atelocollagen-mediated drug discovery technology., Opin. Drug Discov., 2: 159-167, 2007.

2006年

  1. Takeshita F and Ochiya T: Approaches for RNAi therapeutics against cancer. In: RNAi Therapeutics 2006, pp. 101-116. Takaku, H. and Yamamoto, N., ed. Kerala, India: Transworld Research Network, 2006.
  2. Hanai K, Takeshita F, Honma K, Nagahara S, Maeda M, Minakuchi Y, Sano A and Ochiya T: Atelocollagen-mediated systemic DDS for nucleic acid medicines., N. Y. Acad. Sci., 1082: 9-17, 2006.
  3. Takeshita F, Kodama M, Yamamoto H, Ikarashi Y, Ueda S, Teratani T, Yamamoto Y, Tamatani T, Kanegasaki S, Ochiya T and Quinn G: Streptozotocin-induced partial beta cell depletion in nude mice without hyperglycaemia induces pancreatic morphogenesis in transplanted embryonic stem cells., Diabetologia, 49: 2948-2958, 2006.
  4. Yanagihara K, Takigahira M, Takeshita F, Komatsu T, Nishio K, Hasegawa F and Ochiya T: A New Photon Counting Technique for Quantitatively Evaluating Progression of Peritoneal Tumor Dissemination., Cancer Res., 66: 7532-75392006.
  5. Ueda S, Takasuka N, Takeshita F, Naito A, Matsuoka Y, Iigo M, Fukamachi K, Alexander DB, Moore MA, Saito I, Ochiya T and Tsuda H: Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas., Carcinogenesis, 27: 2497-2510, 2006.
  6. Takeshita F and Ochiya T: Therapeutic potential of RNAi against cancer., Cancer Science, 97: 689-696, 2006.
  7. Kosaka N, Kodama M, Sasaki H, Yamamoto Y, Takeshita F, Takahama Y, Sakamoto H, Kato T, Terada M and Ochiya T:FGF-4 regulates neural progenitor cell proliferation and neuronal differentiation., FASEB J., 20: 1484-1485, 2006.

2005年

  1. Takeshita F, Minakuchi Y, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Kato T, Nagahara S, Hanai K, Sano A and Ochiya T: Efficient delivery of siRNA to bone-metastatic tumor using Atelocollagen in vivo., Natl. Acad. Sci. USA, 102: 12177-12182, 2005.
  2. Yoshino H, Futakuchi M, Cho YM, Ogawa K, Takeshita F, Imai N, Tamano S, Shirai T: Modification of an in vivo lung metastasis model of hepatocellular carcinoma by low dose N-nitrosomorpholine and diethylnitrosamine., Exp. Metastasis, 22: 441-447, 2005.

2004年

  1. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, Honma K, Nagahara S, Hanai K, Sano A, Kato T, Terada M and Ochiya T: Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo., Acids Res., 32: e109, 2004.

2003年

  1. Hirai K, Sasaki H, Sakamoto H, Takeshita F, Asano K, Kubota Y, Ochiya T, Terada M: Antisense oligodeoxynucleotide against HST-1/FGF-4 suppresses tumorigenicity of an orthotopic model for human germ cell tumor in nude mice., Gene Med., 5: 951-957, 2003.
  2. Sugiura S, Ogawa K, Hirose M, Takeshita F, Asamoto M, Shirai T: Reversibility of proliferative lesions and induction of non-papillary tumors in rat urinary bladder treated with phenylethyl isothiocyanate., Carcinogenesis, 24: 547-553, 2003.
  3. Takeshita F, Ogawa K, Asamoto M, Shirai T: Mechanistic approach of contrasting modifying effects of caffeine on carcinogenesis in the rat colon and mammary gland induced with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine., Cancer Lett., 194: 25-35, 2003.

2002年

  1. Yamamoto H, Ochiya T, Takeshita F, Toriyama-Baba H, Hirai K, Sasaki H, Sakamoto H, Yoshida T, Saito I and Terada M: Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation., Cancer Res., 62: 1641-1647, 2002.